ArticleScience advances2025
Photoactivatable immunostimulatory nanoengineered microalgae for boosting cascade-activated antitumor immunity.
Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Perovskite immunoadjuvant: Remodeling the immunosuppressive microenvironment via photothermal catalysis to enhance T-cell recruitment and amplify the immune response.Materials today. Bio · 2026Article
- Photothermal-Activable Artificial Macrophage With Amplified Systemic Antibacterial Responses to Combat Primary and Secondary Infection.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- HAdvanced materials (Deerfield Beach, Fla.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Limited tumor immunogenicity and the profoundly immunosuppressive tumor microenvironment (TME) pose major challenges to effective cancer immunotherapy. Herein, we present a photoactivatable immunostimulator based on nanoengineered microalgae (PCC@AuNP) to simultaneously enhance tumor immunogenicity and remodel the TME. Mechanistically, photocatalytically generated hydrogen induces robust immunogenic cell death by triggering severe endoplasmic reticulum stress and mitochondrial dysfunction. Concurrently, photosynthetic oxygen production and photocatalytic lactic acid depletion collaboratively alleviate immunosuppression within the TME, thereby enhancing cytotoxic T lymphocyte activity by reducing the infiltration of immunosuppressive cells and promoting the repolarization of tumor-associated macrophages from the M2 to the M1 phenotype. In vivo studies demonstrate that PCC@AuNP not only eradicates primary tumors but also elicits potent systemic antitumor immunity against distant lesions, without observable toxicity to healthy tissues. Collectively, this innovative PCC@AuNP platform offers a safe and effective therapeutic strategy, heralding a pioneering era of cascade-augmented gas-driven cancer immunotherapy with superior precision and biosafety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.